SFC
SABS icon

Strategic Financial Concepts’s SAB Biotherapeutics SABS Stock Holding History

Strategic Financial Concepts’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,503
Closed -$9.47K – 235
2023
Q3 		$9.47K Hold
1,503
– – ﹤0.01% 267
2023
Q2 		$12.5K Hold
1,503
– – ﹤0.01% 254
2023
Q1 		$6.61K Buy
+1,503
New +$9.51K ﹤0.01% 241

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Financial Concepts's SABS Position: Q4 2023 in Review

Strategic Financial Concepts sold out of SAB Biotherapeutics (SABS) in Q4 2023, closing a stake of 1,503 shares — an estimated $9.47K sold.

Strategic Financial Concepts first reported a position in SABS in Q1 2023 and held it in 3 quarters. The position peaked at $12.5K in Q2 2023. 42 funds tracked by Wall St. Rank hold SABS as of Q4 2023.

  • Strategic Financial Concepts reported no remaining SAB Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Strategic Financial Concepts sold 1,503 SAB Biotherapeutics shares in Q4 2023, an estimated $9.47K.
  • Strategic Financial Concepts first reported a position in SAB Biotherapeutics in Q1 2023 and held it in 3 quarters.
  • Strategic Financial Concepts's SAB Biotherapeutics position peaked at $12.5K in Q2 2023.
  • 42 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2023.

Based on Strategic Financial Concepts's 13F filing for Q4 2023, filed 18 Jan 2024.